MSK
Search
- Page Path
- HOME > Search
Review
- Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines
- Heedo Park , Mee Sook Park , Jong Hyeon Seok , Jaehwan You , Jineui Kim , Jeonghun Kim , Man-Seong Park
- J. Microbiol. 2022;60(3):308-320. Published online March 2, 2022
- DOI: https://doi.org/10.1007/s12275-022-1598-x
- 58 View
- 0 Download
- 5 Web of Science
- 6 Crossref
-
Abstract
- The three types of approved coronavirus disease 2019 (COVID- 19) vaccines that have been emergency-use listed (EUL) by the World Health Organization are mRNA vaccines, adenovirus- vectored vaccines, and inactivated vaccines. Canonical vaccine developments usually take years or decades to be completed to commercialization; however, the EUL vaccines being used in the current situation comprise several COVID- 19 vaccine candidates applied in studies and clinical settings across the world. The extraordinary circumstances of the COVID-19 pandemic have necessitated the emergency authorization of these EUL vaccines, which have been rapidly developed. Although the benefits of the EUL vaccines outweigh their adverse effects, there have been reports of rare but fatal cases directly associated with COVID-19 vaccinations. Thus, a reassessment of the immunological rationale underlying EUL vaccines in relation to COVID-19 caused by SARSCOV- 2 virus infection is now required. In this review, we discuss the manifestations of COVID-19, immunologically projected effects of EUL vaccines, reported immune responses, informed issues related to COVID-19 vaccination, and the potential strategies for future vaccine use against antigenic variants.
-
Citations
Citations to this article as recorded by
- Single intranasal immunization with attenuated Wuhan-like SARS-CoV-2 provides highly effective cross-protection against Delta and Omicron variants of concern
Evgeny B. Faizuloev, Anastasiia V. Gracheva, Ekaterina R. Korchevaya, Yulia I. Ammour, Daria I. Smirnova, Darya M. Khokhlova, Andrey O. Drokov, Andrey A. Pankratov, Galina V. Trunova, Varvara A. Khokhlova, Maria S. Vorontsova, Irina A. Leneva, Oksana A. S
Journal of microbiology, epidemiology and immunobiology.2024; 101(1): 36. CrossRef - Real-time infectious disease endurance indicator system for scientific decisions using machine learning and rapid data processing
Shivendra Dubey, Dinesh Kumar Verma, Mahesh Kumar
PeerJ Computer Science.2024; 10: e2062. CrossRef - A systematic review and meta-analysis of the seroconversion rates and adverse effects of COVID-19 mRNA vaccine and COVID-19 viral vector vaccine in kidney transplant recipient patients
Sikai Chen, Wenxin Wei, Fengyu Huang, Jing Wang, Xingyu Li, Zhixin Geng, Feng Gao, Taiwei Dong, Peifeng Wei, Xinbo Yang, Feng Miao
Human Vaccines & Immunotherapeutics.2023;[Epub] CrossRef - Extracellular Vesicle-Based SARS-CoV-2 Vaccine
Yasunari Matsuzaka, Ryu Yashiro
Vaccines.2023; 11(3): 539. CrossRef - Immunity after COVID-19 Recovery and Vaccination: Similarities and Differences
Dorota Kamińska, Dominika Dęborska-Materkowska, Katarzyna Kościelska-Kasprzak, Oktawia Mazanowska, Agata Remiorz, Paweł Poznański, Magdalena Durlik, Magdalena Krajewska
Vaccines.2022; 10(7): 1068. CrossRef - Two years of COVID-19 pandemic: where are we now?
Jinjong Myoung
Journal of Microbiology.2022; 60(3): 235. CrossRef
- Single intranasal immunization with attenuated Wuhan-like SARS-CoV-2 provides highly effective cross-protection against Delta and Omicron variants of concern
First
Prev
TOP
